GCT is proud to announce that it has been awarded a new project focusing on an Acute Ischemic Stroke (AIS) study across sites in Eastern Europe. This important study aims to evaluate the safety and efficacy of an investigational product (IP) for treating participants with moderate stroke severity, who present within 24 hours of AIS onset due to small and medium vessel occlusions, and who have limited treatment options. Treatment constraints may be due to the location of the clot, comorbidity risks, or the time elapsed since the estimated onset of the stroke. Participants who have or will receive mechanical thrombectomy (MT) will be excluded, as well as participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment.
GCT has already commenced project set-up activities, including site qualification visits and regulatory submission preparation.
Dr. Eugene Selivra, GCT CEO, commented, “We are excited to embark on this significant project that has the potential to bring new treatment options to those affected by acute ischemic stroke. Our dedicated team is committed to advancing medical research and improving patient outcomes.”
Stay tuned for more updates as we progress with this groundbreaking study.